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Abstract
Purpose: In diseases such as proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy, and age-related
macular degeneration, retinal pigment epithelial (RPE) cells proliferate and migrate. Moreover, platelet-derived growth
factor (PDGF) has been shown to enhance proliferation and migration of RPE cells in PVR. Even resveratrol can suppress the
migration and adhesion of many cell types, its effects on RPE cell migration and adhesion remain unknown. In this study, we
investigated the inhibitory effects of resveratrol on RPE cell migration induced by PDGF-BB, an isoform of PDGF, and
adhesion to fibronectin, a major ECM component of PVR tissue.
Methods: The migration of RPE cells was assessed by an electric cell-substrate impedance sensing migration assay and a
Transwell migration assay. A cell viability assay was used to determine the viability of resveratrol treated-cells. The cell
adhesion to fibronectin was examined by an adhesion assay. The interactions of resveratrol with PDGF-BB were analyzed by
a dot binding assay. The PDGF-BB-induced signaling pathways were determined by western blotting and scratch wound
healing assay.
Results: Resveratrol inhibited PDGF-BB-induced RPE cell migration in a dose-dependent manner, but showed no effects on
ARPE19 cell adhesion to fibronectin. The cell viability assay showed no cytotoxicity of resveratrol on RPE cells and the dot
binding assay revealed no direct interactions of resveratrol with PDGF-BB. Inhibitory effects of resveratrol on PDGF-BB-
induced platelet-derived growth factor receptor b (PDGFRb) and tyrosine phosphorylation and the underlying pathways of
PI3K/Akt, ERK and p38 activation were found; however, resveratrol and PDGF-BB showed no effects on PDGFRa and JNK
activation. Scratch wound healing assay demonstrated resveratrol and the specific inhibitors of PDGFR, PI3K, MEK or p38
suppressed PDGF-BB-induced cell migration.
Conclusions: These results indicate that resveratrol is an effective inhibitor of PDGF-BB-induced RPE cell migration via
PDGFRb, PI3K/Akt and MAPK pathways, but has no effects on the RPE cell adhesion to fibronectin.
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Introduction
Cells of the retinal pigment epithelium (RPE) form a highly
specialized monolayer between Bruch `s membrane and the choroid
on their basal side and the neurosensory retina on their apical side.
The cells play important roles in eye development and visual
function. They allow transportation of nutrients from the choroid
to the photoreceptors, recognition of the light cycle, maintenance
of the blood–retinal barrier, and phagocytosis of shed photore-
ceptor outer segments. In diseases such as age-related macular
degeneration (AMD)[1], proliferative vitreoretinopathy
(PVR)[2,3,4] and proliferative diabetic retinopathy (PDR)[5],
RPE cell migration may result in severe visual impairment[5].
RPE cell migration is a complex molecular process regulated by
growth factors and cytokines. Among the growth factors, PDGF
exhibits more chemotactic and proliferative effects than others on
RPE cells[6], is important for development of PVR and
fibrovascular membrane (FVM) in PDR[7].
Resveratrol (3,5,49-trihydroxystilbene), a major polyphenol
found in grapes, red wine, peanuts, and other plants[8,9], has
been shown to be involved in antioxidant[10,11], anti-prolifera-
tive[12,13,14], anti-inflammatory[15,16] and chemopreven-
tive[17] activities. A number of potential health benefits, including
reduced risk of cancer[18,19,20] and heart disease[21,22], are
thought to be associated with consumption of resveratrol.
However, its effects on the retina have not been well documented.
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56819Our previous studies have demonstrated that lycopene and
epigallocatechin gallate (EGCG) can inhibit PDGF-BB-induced
signaling and migration of adult human retinal epithelial
(ARPE19) cells through direct binding with PDGF-BB[23,24]. In
this study, we investigated the inhibitory effect of resveratrol on
PDGF-BB-induced ARPE19 cell migration and the potential
mechanisms involved. These mechanisms include the influence of
resveratrol on ARPE19 cell adhesion, viability, the expression of
anti-phosphotyrosine antibodies (4G10), platelet-derived growth
factor receptor b (PDGFRb), phosphatidylinositol-3 kinase
(PI3K)/Akt pathway activation and mitogen-activated protein
kinase (MAPK) activation.
Materials and Methods
Materials
Resveratrol, bovine serum albumin (BSA), aprotinin, leupeptin,
phenylmethylsulfonyl fluoride (PMSF), sodium fluoride (NaF),
sodium orthovanadate, mitomycin-C, LY294002, U0126,
SP600125 and SB203580 were purchased from Sigma Chemical
Co. (St Louis, MO, USA). AG1295 was purchased from Merck
KGaA. (Darmstadt, Germany). Human plasma fibronectin was
from Life Technologies Corporation (Carlsbad, CA, USA).
Antibodies (Ab) raised against PDGFRband phospho-extracellular
signal-regulated kinase 1/2 (ERK1/2) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Ab raised against
phosphotyrosine (4G10) was from EMD Millipore Corporation
(Billerica, MA, USA). Abs raised against phospho-PDGFRa,
phospho-PDGFRb, phospho-PI3K, phospho-Akt, Akt, phospho-c-
Jun N-terminal kinase (JNK), phospho-p38 and p38 were from
Cell Signaling Technology, Inc. (Beverly, MA, USA). Abs raised
against total ERK1/2 and JNK were from R&D systems, Inc.
(Minneapolis, MN, USA).
Cell cultures
ARPE19 cells were purchased from Food Industry Research
and Development Institute (Hsinchu, Taiwan) and were main-
tained in DMEM/F12 supplemented with 10% fetal bovine serum
(GibcoBRL, Invitrogen Life Technologies, Carlsbad, CA), 100
units/ml penicillin, and 100 mg/ml streptomycin (Sigma Chem-
ical Co., St. Louis, MO). The cells were cultured in a humidified
incubator at 37uC and 5% CO2. For most of the experiments, cells
reaching a 90%–95% of confluence were starved and synchro-
nized in serum-free DMEM/F12 for 24 hours before they were
subjected to further analysis.
Resveratrol treatment and PDGF-BB incorporation
Resveratrol was dissolved in dimethyl sulfoxide (DMSO) to the
desired concentrations. In migration assays and the Western blot
analysis, the serum-free cell culture medium with various
concentrations of resveratrol were all preincubated with or
without PDGF-BB (20 ng/ml) at 37uC for 30 minutes.
ECIS migration assays
ECIS migration assays were conducted with the Electric Cell-
Substrate Impedance Sensing (ECIS) system (Applied Biophysics,
Inc., Troy, NY). ARPE19 cells were cultured in 8W1E ECIS
arrays (Applied Biophysics), where each well for cell culture
contained a small gold film circular electrode (5610
24 cm
2) and a
larger (0.15 cm
2) counter electrode. The electrodes were connect-
ed to the ECIS 1600R instrument that applied an approximately
constant AC current (1 mA at 4,000 Hz) between the two
electrodes using culture medium as the electrolyte. The instrument
monitored both the voltage across the electrodes and the phase
relative to the applied current. From this information, the
instrument reported the impedance, resistance and capacitance
of the small electrode, treating the system as a series RC circuit. As
the cells attached and spread on the small electrode, their
membranes constricted the current and forced it to flow in the
space beneath the basal membrane and the electrode surface and
in the paracellular path between adjacent cells (the barrier
function), resulting in a significant increase in impedance. The
microampere current and the resulting voltage drop of a few
millivolts have been shown to have no measurable effect on the
cells, and hence, the monitoring of cell behavior was noninvasive
[25].
We seeded ARPE19 cells at a concentration of 70,000 cells/
well in the arrays and incubated them for 24 hours. The
experiments were conducted on wells where the electrode
resistance had achieved a steady state. After being submitted to
an elevated voltage pulse of 40-kHz frequency, 4-V amplitude,
and 10-s duration, which led to death and detachment of cells
present on the small active electrode, the medium was changed to
a serum-free cell culture medium containing various concentra-
tions of resveratrol preincubated with or without PDGF-BB
(20 ng/ml) at 37uC for 30 minutes. Cells surrounding the small
active electrode that had not been submitted to the elevated
voltage pulse then migrated inward to replace the killed cells. Cell
migration was assessed by continuous resistance measurements
for 30 hours.
Transwell migration assays
Transwell migration assays with ARPE19 cells were performed
by using a modified Boyden chamber model (Transwell apparatus,
8.0 mmpore size, Costar)[26]. For detection of ARPE19 cell
migration in the Transwell, the lower face of polycarbonate filters
(Transwell insert) were coated with fibronectin (0.3 mg) for 30
minutes in the laminar flow hood. The lower chamber was filled
with 0.6 ml of serum-free medium or PDGF-BB (20 ng/ml)-
containing medium which was preincubated with various concen-
trations of resveratrol. ARPE19 cells (5610
4 cells, 200 ml) were
plated to the upper chamber. After 5 hours of incubation, all cells
that had not migrated were removed from the upper face of the
Transwell membrane with a cotton swab and migrated cells were
fixed and stained with 0.5% toluidene blue in 4% PAF. Migration
was quantified by counting the number of stained cells per 6100
field (high power field, HPF) with a phase-contrast microscope
(Leica DMIL1) and photographed.
Cell viability assays
The viability of cells was determined by the MTT. The MTT
assay in our laboratory has been previously described[27]. Briefly,
resveratrol-treated cells were incubated for 24 hours. After a brief
wash with medium, 0.5 mg/ml MTT in DMEM was used for the
quantification of living and metabolically active cells. Mitochon-
drial dehydrogenases metabolized MTT to a purple formazan dye,
which was analyzed photometrically at 550 nm. Cell viability was
proportional to the absorbance measured.
Adhesion assays
96-well plates were coated with 50 ml fibronectin (15 mg/ml in
PBS, pH 7.4) per well and incubated at 37uC for 24 hours. After
being washed with PBS three times, the unspecific binding of
fibronectin on the plates was blocked by 100 mg/ml bovine serum
albumin (Sigma-Aldrich) in PBS at room temperature for 1 hour.
ARPE19 cells were trypsinized and resuspended in serum-free cell
culture medium and labeled with BCECF/AM (10 mg/ml) for 30
minutes at 37uC. After being washed with the serum-free cell
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free cell culture medium with different concentrations of
resveratrol to a density of 1.0610
5 cells/ml and incubated for
another 30 minutes at 37uC. Then the suspended cells were
applied onto 96-well plates within 100 ml serum-free cell culture
medium with different concentrations of resveratrol per well and
incubated at 37uC for 1 hour. After being gently washed with PBS
three times, the nonadherent cells were removed by aspiration and
the 96-well plates were subjected to measurement by Wallac
Victor 3 1420 multilabel counter (Perkin Elmer, Turku, Finland)
using excitation and emission wavelength of 485 and 535 nm,
respectively.
Dot binding assay
A nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA) was soaked in a buffer (25 mM Tris, 192 mM glycine and
20% methanol) for 30 seconds. Recombinant PDGF-BB (2 mg/
ml in 50 ml) was applied to the membrane with a Bio-Dot
microfiltration apparatus (Bio-Rad Laboratories, Hercules, CA)
by suction. 2.5 mlo fD M S O ,3mMa n d1 0mM of resveratrol
were directly spotted on the same membrane. The membrane
was then blocked with BSA (5% in PBS) for 0.5 hour. After being
washed with PBS, the membrane was incubated with PDGF-BB
(0.5 mg/ml) in PBS for 1 hour at room temperature (RT). A brief
wash was followed, and the membrane was then incubated with
anti-PDGF-BB Ab (2 mg/ml in 1% BSA-containing PBS) for
1 hour at RT. After another brief wash, the membrane was
incubated with horseradish peroxidase-conjugated Ab before
being developed by enhanced chemiluminescence (ECL; NEN,
Boston, MA).
Cell lysate preparation and Western blot analysis
ARPE19 cells cultured on 6 cm dishes were starved for
24 hours and then treated with various concentrations of
resveratrol which were preincubated with or without PDGF-BB
(20 ng/ml) at 37uC for 30 minutes. After 10 or 30 minutes of
further incubation, the ARPE19 cells were washed with PBS
twice and the phosphorylation of the tyrosine (4G10), PDGFRa,
PDGFRb, PI3K, Akt, ERK, JNK and p38 were analysed. They
were then lysed in radioimmunoprecipitation assay buffer
[17 mM Tris–HCl, pH 7.4, 50 mM NaCl, 5 mM EDTA.
1 mM sodium fluoride, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM PMSF,
and 1 mg/ml aprotinin and leupeptin (freshly prepared)]. After
sonication, the lysate was centrifuged (14,000 g for 10 minutes at
4uC), and the supernatant was removed. The protein content was
quantified by a Pierce protein assay kit (Pierce, Rockford, IL).
Total protein was separated by electrophoresis on 8% SDS–
polyacrylamide gels. The proteins were then electroblotted onto
polyvinylidene fluoride PVDF membranes and probed using the
indicated antibodies. Immunoblots were detected by enhanced
chemiluminescence (Chemiluminescence Reagent Plus from
NEN, Boston, MA). For some of the experiments, the PVDF
membrane was stripped at 60uC for 30 minutes with a stripping
buffer (62.5 mM Tris-HCl, pH 6.7, 2% SDS and 100 mM b-
mercaptoethanol).
Scratch wound healing assay
In vitro scratch wound healing assay was created by scraping
the cell monolayer with a linear scratching with a sterile 20- ml
pipette tip. The cells were immediately washed and wound closure
with various treatments was monitored for a maximum of 16 h
Figure 1. PDGF-BB-induced ARPE19 cell migration was inhibited by resveratrol in an ECIS migration assay. The cells cultured in 8W1E
ECIS arrays were treated with different combinations of PDGF-BB (20 ng/ml) and resveratrol (CTL indicates that it contained only DMSO) which were
preincubated together at 37uC for 30 minutes. Cell migration was then assessed by continuous resistance measurements for 30 hours. Resveratrol
(Res) (10 mM) did not increased cell migration when PDGF-BB was not present. In the well containing PDGF-BB but not resveratrol, the impedance,
which corresponds to the number of cells migrated to the surface of the detective electrode, increased sharply during the first 10 hours. By contrast,
the impedance in the well containing PDGF-BB and resveratrol increased slowly during the same time period.
doi:10.1371/journal.pone.0056819.g001
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DMIL1). Assays were performed in the presence of mitomycin-C
(5 mg/ml) for 1 hour to prevent proliferation of RPE cells.
Migration was quantified by counting the number of migrated
cells per 6100 field (high power field, HPF).
Statistical analysis
All data were analyzed with SigmaPlot for Windows (Version
10.00). Data are expressed as mean 6 standard error (SE) of four
experiments. Comparison of means between two groups of data
was made using the unpaired, two-tailed Student t test.
Results
Resveratrol inhibited PDGF-BB-induced ARPE19 cell
migration
To determine the inhibitory effects of resveratrol on ARPE19
cell migration, we first performed ECIS migration assays. The
results show that ARPE19 cell migration was promoted by PDGF-
BB and the promotive effect was conspicuously suppressed by the
preincubation of PDGF-BB with resveratrol. However, resveratrol
did not inhibit ARPE19 cell migration in the samples without
PDGF-BB (Figure 1). We also conducted Transwell migration
assays to compare the results with the ECIS migration assays.
Figure 2. Transwell migration assay showed that PDGF-BB-induced ARPE19 cell migration was inhibited by resveratrol. Transwell
inserts were coated with fibronectin (0.3 mg). ARPE19 cells (5610
4 in 200 ml) were seeded in the upper chamber in the absence or presence of
resveratrol. The inserts were assembled in the lower chamber, which was filled with 600 ml serum-free medium without PDGF-BB (A) and containing
PDGF-BB (20 ng/ml) (B), and preincubated with various concentrations of resveratrol for 30 mininutes at 37uC. After incubating for 5 hours at 37uC,
fixation was performed. ARPE19 cells that migrated to the underside of filter membrane were photographed (A, B) and counted by phase contrast
light microscope under high power field (magnification, 1006), (C). All experiments were conducted in duplicates and similar results were repeated
four times. The results are expressed as percentage of control and represent mean 6 standard errors (SE) of the eight experiments. *p,0.05
significantly differs from PDGF-BB-stimulated cells (the fourth bar).
doi:10.1371/journal.pone.0056819.g002
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fibronectin was observed in the absence of PDGF-BB, with about
20 migrated cells found in HPF, suggesting that fibronectin is a
‘chemoattractant’ for ARPE19 cells. PDGF-BB stimulated
ARPE19 cell migration to about two folds over that elicited by
fibronectin alone. However, resveratrol abolished the PDGF-BB-
induced ARPE19 cell migration on fibronectin (Figure 2B).
Quantitative analysis indicates that nearly 100% of migration
was inhibited by 10 mM of resveratrol (Figure 2C). These
observations indicate that resveratrol is effective in the prevention
of PDGF-BB-induced ARPE19 cell migration.
Resveratrol showed no cytotoxicity on ARPE19 cells
To exclude the possibility that resveratrol affects ARPE19 cell
migration through its effects on cell viability, cell viability assays
were performed. As shown in Figure 3A, resveratrol treatments (1,
Figure 3. Viability and cell adhesion of ARPE19 cells was not influenced by resveratrol. The cells were treated with different
concentrations of resveratrol for 24 hours after being starved for 24 hours. Cell viability was determined by MTT assay (A). BCECF-labeled cells were
treated with DMSO or resveratrol for 30 minutes. They were then seeded and allowed to adhere on plates with precoated fibronectin (fn) (15 mg/ml)
at 37uC for 1 hour. Fluorescence was measured using excitation and emission wavelength of 485 and 535 nm, respectively (B). The results are
expressed as percentage of control and represent the mean 6 standard errors (SE) of four independent experiments.
doi:10.1371/journal.pone.0056819.g003
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results indicate that resveratrol is safe for ARPE19 cells and its
effects on ARPE19 cell migration did not result from the decrease
of cell viability.
Resveratrol showed no effect on ARPE19 cell adhesion
To determine whether resveratrol inhibited ARPE19 cell
migration through interfering with their attachment to fibronectin,
we tested the effect of resveratrol on ARPE19 cell adhesion with
fibronectin coated. As shown in Figure 3B, the amount of cell
adhesion was not affected by the presence of resveratrol. The
observation indicates that the inhibitory effect of resveratrol on
ARPE19 cell migration was not induced by interfering with the
attachment of the cells to fibronectin.
Resveratrol did not directly bind to platelet-derived
growth factor-BB in dot binding assay
Recombinant human PDGF-BB and resveratrol were immobi-
lized on the nitrocellulose (NC) membrane. After incubation with
or without PDGF-BB, the membrane was further incubated with
antibodies against PDGF-BB and then developed. We observed
that immobilized PDGF-BB can be recognized by the anti-PDGF-
BB Ab, suggesting the specificity of Ab. But the 3 mM and 10 mM
of resveratrol did not directly bind to PDGF-BB. The data
indicates that resveratrol cannot directly bind to PDGF-BB
(Figure 4).
Resveratrol inhibited PDGF-BB-induced PDGFRb
phosphorylation and downstream PI3K/Akt and MAPK
pathway activation
It has been reported that PDGF-BB binding to PDGF receptors
(PDGFR) is associated with the dimerization, autophosphory-
lation, and activation of PDGFR-tyrosine kinase activity[28]. To
determine whether PDGF-BB-induced signaling pathways are
affected by resveratrol, the extent of phosphorylation of PDGFR
and its downstream components in ARPE19 cells was evaluated.
Figure 5 shows that stimulation of ARPE19 cells with PDGF-BB
resulted in PDGFRb phosphorylation, as determined by Western
blotting with antibody directed against tyrosine, PDGFRb.
Preincubation of PDGF-BB with resveratrol resulted in the
inhibition of tyrosine, PDGFRb phosphorylation in a time- and
concentration-dependent manner. There was no PDGFRa
phosphorylation under PDGF-BB stimulation or resveratrol
preincubation. Figure 6 shows that PI3K and Akt phosphorylation
were also increased by PDGF-BB stimulation. Preincubation of
PDGF-BB with resveratrol resulted in the decrease of PI3K and
Akt phosphorylation in a time- and concentration-dependent
manner. Among MAPKs, ERK and p38 phosphorylation
increased after being stimulated with PDGF-BB and the increase
was suppressed by preincubation of PDGF-BB with resveratrol in
a concentration-dependent manner (Figure 7), while JNK
phosphorylation was not influenced by PDGF-BB stimulation or
resveratrol preincubation.
PDGF-BB-induced cell migration was inhibited by
resveratrol and by suppression of PDGFR, PI3K/Akt and
MAPK signaling
The migration of ARPE19 cells with various treatments was
assessed using a scratch wound healing assay. Incubation of
ARPE19 with PDGF-BB brought about an increase in the
migration of ARPE19 cells. Then, we assessed the effects of
resveratrol, PDGFR tyrosine kinase blocker inhibitor AG1295,
PI3K inhibitor LY294002, MEK inhibitor U0126, JNK inhibitor
SP600125 and P38 inhibitor SB203580 on PDGF-BB-induced
migration of RPE cells. Figure 8 shows enhanced migration of
RPE cells with significant wound closure by 16 h in the plates
incubated with PDGF-BB (20 ng/ml) only, but a significant area
of the wound remaining uncovered in the plates treated with
resveratrol (10 mM) in the presence of PDGF-BB. Moreover, the
suppression of PDGF-BB induced cell migration was observed in
the plates incubated with AG1295 (10 mM), LY294002 (10 mM),
U0126 (10 mM) and SB203580 (3 mM) respectively, indicating the
possible involvement of the PI3K/Akt, ERK and p38 pathways
and the signaling events by which resveratrol blocks PDGF-BB-
induced RPE cell migration. Incubation with SP600125 (3 mM)
did not show the inhibitory effect in RPE migration in the
presence of PDGF-BB. Our result shows that the PDGF-BB-
induced migration of ARPE19 cells is inhibited by resveratrol and
mediated through PDGFR, PI3K/Akt, ERK and p38 signaling.
Discussion
There are two PDGF peptides encoded by two different genes:
PDGF-A and PDGF-B. The mature peptides are approximately
100 aa long and share 60% sequence similarity. The biologically
active PDGF molecules are either homodimers (PDGF-AA and
PDGF-BB) or heterodimers (PDGF-AB) that are formed by two
disulphide bonds between the monomers[29,30,31]. PDGF dimers
exert their effects on target cells by binding to cell surface receptors
(PDGFRa and PDGFRb) that contain five IgG-like domains
extracellularly and an intracellular tyrosine kinase domain.
PDGFRa binds to both A and B chains while PDGFRbbinds
only to B chain with high affinity. PDGFR dimerization is driven
by ligand binding; PDGF-AA induces the aa receptor dimers, AB
the aa and ab receptor dimers, and BB all three combinations of
receptor dimers[32]. The expression of PDGF-A and -B genes and
their receptors are independently regulated, and depend on cell
types and physio-pathological conditions[30]. Recently, two new
PDGF genes, PDGF-C and PDGF-D have been discovered, and
their protein products are secreted as latent factors that require
activation by proteolysis[33]. PDGF-C and -D form only
homodimers that bind to PDGFRa and PDGFRb, respectively,
with high affinity. Although the expression of PDGF-C and -D has
been demonstrated in a variety of cells, including cancer cells, their
functional significance and physiological roles are much less
understood than PDGF-A and -B.
Proliferative vitreoretinal diseases, such as PVR and PDR, are
major causes of retinal detachment and result from the formation
Figure 4. Resveratrol did not directly interact with PDGF-BB in
dot binding assay. Human recombinant PDGF-BB, phosphate buffer
saline (PBS) and the indicated concentrations of resveratrol were
applied onto the nitrocellulose (NC) membrane. The membrane was
incubated with PDGF-BB in PBS and then developed by probing with
Ab directed against PDGF-BB. The results presented are representative
of four independent experiments.
doi:10.1371/journal.pone.0056819.g004
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PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e56819Figure 5. PDGF-BB-induced tyrosine and PDGFRb phosphorylations were inhibited by resveratrol in a time- and concentration-
dependant manner. ARPE19 cells were treated with the indicated lengths of time of PDGF-BB (20 ng/ml) and preincubated with or without
resveratrol (10 mM) at 37uC (A). After being further preincubated for the indicated concentrations of resveratrol and incubated with or without PDGF-
BB (20 ng/ml) at 37uC for 30 minutes, the cells were collected and their lysates were analyzed by Western blot analysis (B). The changes in
phosphorylated tyrosine, PDGFRa and PDGFRb expression were evaluated. The quantitative data of western blot are shown below the panels which
are expressed as percentage of control and represent mean 6 standard errors (SE) of the four independent experiments. *p,0.05 significantly differs
from same indicated time of cells stimulated PDGF-BB only (A) and *p,0.05 significantly differs from PDGF-BB-stimulated cells (the fifth bar) (B).
doi:10.1371/journal.pone.0056819.g005
Figure 6. PDGF-BB-induced PI3K and Akt phosphorylations were inhibited by resveratrol in a time- and concentration-dependant
manner. ARPE19 cells were treated with the indicated lengths of time of PDGF-BB (20 ng/ml) and preincubated with or without resveratrol (10 mM)
at 37uC (A). After being further preincubated for the indicated concentrations of resveratrol and incubated with or without PDGF-BB (20 ng/ml) at
37uC for 30 minutes, the cells were collected and their lysates were analyzed by Western blot analysis (B). The changes in phosphorylated PI3K and
Akt expression were evaluated. The quantitative data of western blot are shown below the panels which are expressed as percentage of control and
represent mean 6 standard errors (SE) of the four independent experiments. *p,0.05 significantly differs from same indicated time of cells
stimulated PDGF-BB only (A) and *p,0.05 significantly differs from PDGF-BB-stimulated cells (the fifth bar) (B).
doi:10.1371/journal.pone.0056819.g006
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or within the vitreous[34,35]. Elevated expression of PDGF has
been observed in RPE cells after retinal detachments or retinal
laser treatment in murine model systems[36]. Expression of
PDGF-A, -B and PDGFRb has also been shown in in vitro
wounded human RPE cell cultures[36]. In immunohistochemical
studies with epiretinal membranes isolated from PVR and PDR
patients, PDGF and PDGFRawere found to be elevated[7,37].
The role of PDGF in PVR has been clearly demonstrated in
transgenic mice expressing PDGF-A or PDGF-B in photorecep-
tors by using rhodopsin promoter[38,39]. PDGF-A overexpression
led to proliferation of glial cells and traction retinal detachment
without the involvement of vascular cells. PDGF-B overexpression
resulted in traction retinal detachment involving proliferation of
both vascular and non-vascular cells similar to that observed in
diabetic retinopathy[39] In this PDGF transgenic mouse model,
the kinase inhibitor PKC412 was shown to suppress ERM
formation and retinal detachment[40]. In studies involving
experimental PVR in rabbits, PDGF receptor kinase inhibitor
has been shown to attenuate PVR significantly[41]. Moreover,
dominant negative mutants of PDGFRacan attenuate the
development of PVR[42,43] and blocking signaling events by
which the non-PDGFs indirectly activated PDGFRa protected
rabbits from developing PVR[44]. It has been shown that even
though RPE cells express PDGFRa substantially less than
fibroblasts, they significantly boost PVR-related signaling events,
cellular responses, and the PVR potential of ARPE19 cells[44,45].
In FVM membrane of PDR, the contribution of RPE cells has
been confirmed by ultrastructural investigation[46,47]. The RPE
layer is known to undergo the earliest pathological change in the
diabetic retina[48]. Furthermore, patients with PDR typically
have 5%–20% of RPE cells in combined traction rhegmatogenous
retinal detachment membrane[46]. These observations indicate
that RPE cells migrate through the retinal breaks to access the
PDR membrane and may contribute to PDR progression by
secreting angiogenic factors. High retinal expression of PDGF-B is
observed homozygous rho/PDGF-B (rho/PDGF-BB) mice that
results in traction retinal detachment from proliferation of both
vascular and nonvascular cells, similar to diabetic retinopathy in
humans[39]. It has been shown that a single intravitreous injection
of an aptamer that specifically binds to PDGF-B is able to
significantly reduce epiretinal membrane formation and retinal
detachment in rho/PDGF-B mice[49]. Elevated concentration of
PDGF-BB in vitreous fluid is seen in diabetic retinopathy and
central retinal vein occlusion[50]. The level of PDGF isoforms in
the vitreous, but not in serum, has been shown to correlate to the
pathology of PDR. Thus, down-regulation of PDGF isoforms
offers a potential target for the treatment of PDR[51].
Resveratrol, a stilbenoid compound found in red grapes and red
wine, has shown inhibitory effects on cell migration in different cell
lines. It can effectively and efficiently suppress endothelial cell
proliferation and migration, with low cytotoxicity, in the ARPE19
and HUVEC lines[52]. Moreover, there have been observations of
inhibitory effects on smooth muscle cell migration[53] and tumor
necrosis factor-alpha-induced monocyte adhesion and migra-
tion[54]. Furthermore, resveratrol has been shown to inhibit
endothelial cell migration and monocyte monocyte chemoattrac-
tant protein-induced (MCP-1) monocytic cell chemotaxis[55]. In
breast-cancer cells, resveratrol has been reported to inhibit
migration and invasion of cells through the suppression of the
activation of PI3K/Akt signaling pathway[56], and epidermal
growth factor (EGF)-induced migration, presumably through the
EGFR/PI3K signaling pathway[57]. Through inhibition of PDGF
signaling, vitisin B, the resveratrol tetramer, has been shown to
inhibit cell migration in cultured vascular smooth muscle cells[58].
In the early stages of PVR, provisional ECM components
including fibronectin are synthesized and deposited on the retinal
surfaces[59]. Movement of an individual cell from a resting ECM
substrate to a provisional ECM requires initial cell attachment to
the new matrix, followed by cell spreading, stable attachment, and
then migration. After RPE cells establish adhesion, migration
through a retinal hole into the vitreous is a critical stage of PVR
formation. PDGF has been known as a strong chemotactic factor
for RPE cells in the presence of fibronectin[60,61]. In the present
study we found that resveratrol significantly inhibit PDGF-BB-
induced RPE cell migration without any signs of cytotoxicity.
Chemotactic migration is a complex phenomenon involving
adhesion to ECM, cell motility, and the effects of chemotactic
factors[62,63,64]. However, our results indicate that resveratrol
does not affect RPE cell adhesion to fibronectin. The inhibition of
PDGF-BB-induced cell migration by resveratrol and the specific
inhibitors PDGFR, PI3K, MEK or p38 in scratch wound healing
assay coincided with reduced activation of PDGF-BB-induced
PDGFRb, PI3K/Akt, ERK and p38 phosphorylation in Western
blot analysis, suggesting that resveratrol inhibits cell migration via
inhibition of the PDGFRb, PI3K/Akt and MAPKs cascade.
In our system, preincubation of PDGF-BB with resveratrol
resulted in a marked inhibition of its signaling in ARPE19 cells,
including phosphorylation of PDGFRb. Our previous studies have
revealed the inhibitory effects of lycopene and EGCG on PDGF-
BB-induced signaling and migration in ARPE19 cells[23,24]. Our
present findings suggest resveratrol influences PDGF-BB’s function
through similar mechanisms of action in ARPE19 cells. It directly
binds to PDGF-BB, resulting in the blocking of PDGF-BB’s
interaction with its receptors, and inactivates PDGF-BB functions.
As described earlier, proliferation and migration of RPE cells
are proposed to play a significant role in PVR and FVM
progression in PDR. Though resveratrol has been shown to have
the capability to inhibit migration of cancer cells, whether it
possesses the same capability for normal cells has not been
established. In this study, resveratrol is shown to inhibit PDGF-
BB-induced migration and signaling in ARPE19 cells. One
possible mechanism of action is the direct interaction with
PDGF-BB. Further analysis showed that resveratrol inhibited
PDGF-BB-induced signaling in ARPE19 cells. The findings and
concepts presented here provide an important basis for further
investigations to better understand the action mechanisms of
resveratrol in RPE cells and possibly its beneficial effect on the
prevention of FVM in PDR and PVR.
Figure 7. PDGF-BB-induced ERK and P38 phosphorylations were inhibited by resveratrol in a time- and concentration-dependant
manner. ARPE19 cells were treated with the indicated lengths of time of PDGF-BB (20 ng/ml) and preincubated with or without resveratrol (10 mM)
at 37uC (A). After being further preincubated for the indicated concentrations of resveratrol and incubated with or without PDGF-BB (20 ng/ml) at
37uC for 30 minutes, the cells were collected and their lysates were analyzed by Western blot analysis (B). The changes in phosphorylated ERK, JNK
and p38 expression were evaluated. The quantitative data of western blot are shown below the panels which are expressed as percentage of control
and represent mean 6 standard errors (SE) of the four independent experiments. *p,0.05 significantly differs from same indicated time of cells
stimulated PDGF-BB only (A) and *p,0.05 significantly differs from PDGF-BB-stimulated cells (the fifth bar) (B).
doi:10.1371/journal.pone.0056819.g007
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PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e56819Figure 8. PDGF-BB-induced cell migrations were inhibited by resveratrol and by suppression of PDGFR, PI3K/Akt and MAPK
signaling. The plates with confluent monolayer of ARPE cells were pretreated with mitomycin-C (5 mg/ml) for 1 hour, then wounded with a linear
scratching by a sterile 20- ml pipette tip. The cells were immediately washed and were incubated with PDGF-BB (20 ng/ml) only, PDGF-BB in
combination with resveratrol (10 mM), AG1295 (10 mM), LY294002 (10 mM), U0126 (10 mM), SP600125 (3 mM) and SB203580 (3 mM) respectively. The
wound closure was monitored for 16 h followed by photography under phase-contrast microscope (x100) (A). The quantitative data of the number of
migrated cell in the wound area are expressed as percentage of control and represent mean 6 standard errors (SE) of the four independent
experiments. *p,0.05 significantly differs from PDGF-BB-stimulated cells (the second bar) (B).
doi:10.1371/journal.pone.0056819.g008
Inhibition of RPE Cell Migration by Resveratrol
PLOS ONE | www.plosone.org 11 February 2013 | Volume 8 | Issue 2 | e56819Author Contributions
Conceived and designed the experiments: CMC CFH. Performed the
experiments: CMC CFH. Analyzed the data: CMC HHC VCW CLH
CFH. Contributed reagents/materials/analysis tools: CMC CFH. Wrote
the paper: CMC HHC CFH.
References
1. Ho J, Witkin AJ, Liu J, Chen Y, Fujimoto JG, et al. (2011) Documentation of
intraretinal retinal pigment epithelium migration via high-speed ultrahigh-
resolution optical coherence tomography. Ophthalmology 118: 687–693.
2. Charteris DG, Sethi CS, Lewis GP, Fisher SK (2002) Proliferative vitreoretino-
pathy-developments in adjunctive treatment and retinal pathology. Eye (Lond)
16: 369–374.
3. Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, et al. (1997) Post-
traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk
factors, and visual outcome. Ophthalmology 104: 1166–1173.
4. Campochiaro PA (1997) Pathogenic mechanisms in proliferative vitreoretino-
pathy. Arch Ophthalmol 115: 237–241.
5. de Silva DJ, Kwan A, Bunce C, Bainbridge J (2008) Predicting visual outcome
following retinectomy for retinal detachment. Br J Ophthalmol 92: 954–958.
6. Charteris DG (1995) Proliferative vitreoretinopathy: pathobiology, surgical
management, and adjunctive treatment. Br J Ophthalmol 79: 953–960.
7. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, et al. (1994)
Platelet-derived growth factor ligands and receptors immunolocalized in
proliferative retinal diseases. Invest Ophthalmol Vis Sci 35: 3649–3663.
8. Marques FZ, Markus MA, Morris BJ (2009) Resveratrol: cellular actions of a
potent natural chemical that confers a diversity of health benefits. Int J Biochem
Cell Biol 41: 2125–2128.
9. Kiselev KV (2011) Perspectives for production and application of resveratrol.
Appl Microbiol Biotechnol 90: 417–425.
10. Yu W, Fu YC, Wang W (2012) Cellular and molecular effects of resveratrol in
health and disease. J Cell Biochem 113: 752–759.
11. Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D (2012)
Antioxidant effects of resveratrol and other stilbene derivatives on oxidative
stress and *NO bioavailability: Potential benefits to cardiovascular diseases.
Biochimie 94: 269–276.
12. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol
induces growth arrest and apoptosis through activation of FOXO transcription
factors in prostate cancer cells. PLoS One 5: e15288.
13. Lubbers J, Lewis S, Harper E, Hledin MP, Marquez GA, et al. (2011)
Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer
cells. Cell Biol Toxicol 27: 95–105.
14. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, et al. (2010) Resveratrol induces
apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and
inhibits tumor growth in vivo. Cancer Sci 101: 488–493.
15. Wang KT, Chen LG, Tseng SH, Huang JS, Hsieh MS, et al. (2011) Anti-
inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var.
taiwaniana against lipopolysaccharide-induced arthritis. J Agric Food Chem 59:
3649–3656.
16. Csiszar A (2011) Anti-inflammatory effects of resveratrol: possible role in
prevention of age-related cardiovascular disease. Ann N Y Acad Sci 1215: 117–
122.
17. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W (2011)
Chemopreventive effects of resveratrol and resveratrol derivatives.
Ann N Y Acad Sci 1215: 89–95.
18. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al. (2010)
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer
patients. Cancer Res 70: 7392–7399.
19. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. (2010)
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy
volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor
axis. Cancer Res 70: 9003–9011.
20. Huang X, Zhu HL (2011) Resveratrol and its analogues: promising antitumor
agents. Anticancer Agents Med Chem 11: 479–490.
21. Penumathsa SV, Maulik N (2009) Resveratrol: a promising agent in promoting
cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87:
275–286.
22. Petrovski G, Gurusamy N, Das DK (2011) Resveratrol in cardiovascular health
and disease. Ann N Y Acad Sci 1215: 22–33.
23. Chan CM, Huang JH, Chiang HS, Wu WB, Lin HH, et al. (2010) Effects of (-)-
epigallocatechin gallate on RPE cell migration and adhesion. Mol Vis 16: 586–
595.
24. Chan CM, Fang JY, Lin HH, Yang CY, Hung CF (2009) Lycopene inhibits
PDGF-BB-induced retinal pigment epithelial cell migration by suppression of
PI3K/Akt and MAPK pathways. Biochem Biophys Res Commun 388: 172–
176.
25. Giaever I, Keese CR (1991) Micromotion of mammalian cells measured
electrically. Proc Natl Acad Sci U S A 88: 7896–7900.
26. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA (1993) Integrin beta 1-
and beta 3-mediated endothelial cell migration is triggered through distinct
signaling mechanisms. J Cell Biol 121: 163–170.
27. Chan CM, Huang JH, Lin HH, Chiang HS, Chen BH, et al. (2008) Protective
effects of (-)-epigallocatechin gallate on UVA-induced damage in ARPE19 cells.
Mol Vis 14: 2528–2534.
28. Hughes AD, Clunn GF, Refson J, Demoliou-Mason C (1996) Platelet-derived
growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen
Pharmacol 27: 1079–1089.
29. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in
physiology and medicine. Genes Dev 22: 1276–1312.
30. Betsholtz C, Karlsson L, Lindahl P (2001) Developmental roles of platelet-
derived growth factors. Bioessays 23: 494–507.
31. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of
platelet-derived growth factor. Physiol Rev 79: 1283–1316.
32. Rosenkranz S, Kazlauskas A (1999) Evidence for distinct signaling properties
and biological responses induced by the PDGF receptor alpha and beta
subtypes. Growth Factors 16: 201–216.
33. Li X, Eriksson U (2003) Novel PDGF family members: PDGF-C and PDGF-D.
Cytokine Growth Factor Rev 14: 91–98.
34. Pastor JC, de la Rua ER, Martin F (2002) Proliferative vitreoretinopathy: risk
factors and pathobiology. Prog Retin Eye Res 21: 127–144.
35. Pastor JC (1998) Proliferative vitreoretinopathy: an overview. Surv Ophthalmol
43: 3–18.
36. Campochiaro PA, Hackett SF, Vinores SA, Freund J, Csaky C, et al. (1994)
Platelet-derived growth factor is an autocrine growth stimulator in retinal
pigmented epithelial cells. J Cell Sci 107 (Pt 9): 2459–2469.
37. Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, et al. (1995)
Isoforms of platelet-derived growth factor and its receptors in epiretinal
membranes: immunolocalization to retinal pigmented epithelial cells. Exp Eye
Res 60: 607–619.
38. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, et al. (2000)
Photoreceptor-specific expression of platelet-derived growth factor-B results in
traction retinal detachment. Am J Pathol 157: 995–1005.
39. Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, et al. (2002) Retina-specific
expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative
retinopathy. Invest Ophthalmol Vis Sci 43: 2001–2006.
40. Saishin Y, Takahashi K, Seo MS, Melia M, Campochiaro PA (2003) The kinase
inhibitor PKC412 suppresses epiretinal membrane formation and retinal
detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis
Sci 44: 3656–3662.
41. Zheng Y, Ikuno Y, Ohj M, Kusaka S, Jiang R, et al. (2003) Platelet-derived
growth factor receptor kinase inhibitor AG1295 and inhibition of experimental
proliferative vitreoretinopathy. Jpn J Ophthalmol 47: 158–165.
42. Ikuno Y, Leong FL, Kazlauskas A (2000) Attenuation of experimental
proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor
receptor. Invest Ophthalmol Vis Sci 41: 3107–3116.
43. Ikuno Y, Kazlauskas A (2002) An in vivo gene therapy approach for
experimental proliferative vitreoretinopathy using the truncated platelet-derived
growth factor alpha receptor. Invest Ophthalmol Vis Sci 43: 2406–2411.
44. Lei H, Rheaume MA, Kazlauskas A (2010) Recent developments in our
understanding of how platelet-derived growth factor (PDGF) and its receptors
contribute to proliferative vitreoretinopathy. Exp Eye Res 90: 376–381.
45. Lei H, Rheaume MA, Velez G, Mukai S, Kazlauskas A (2011) Expression of
PDGFRalpha is a determinant of the PVR potential of ARPE19 cells. Invest
Ophthalmol Vis Sci 52: 5016–5021.
46. Hiscott P, Gray R, Grierson I, Gregor Z (1994) Cytokeratin-containing cells in
proliferative diabetic retinopathy membranes. Br J Ophthalmol 78: 219–222.
47. Hamilton CW, Chandler D, Klintworth GK, Machemer R (1982) A
transmission and scanning electron microscopic study of surgically excised
preretinal membrane proliferations in diabetes mellitus. Am J Ophthalmol 94:
473–488.
48. Waltman SR, Oestrich C, Krupin T, Hanish S, Ratzan S, et al. (1978)
Quantitative vitreous fluorophotometry. A sensitive technique for measuring
early breakdown of the blood-retinal barrier in young diabetic patients. Diabetes
27: 85–87.
49. Akiyama H, Kachi S, Silva RL, Umeda N, Hackett SF, et al. (2006) Intraocular
injection of an aptamer that binds PDGF-B: a potential treatment for
proliferative retinopathies. J Cell Physiol 207: 407–412.
50. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y (2011) Expression
profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and
central retinal vein occlusion. Jpn J Ophthalmol 55: 256–263.
51. Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, et al.
(2009) Vitreous and serum levels of platelet-derived growth factor and their
correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 34:
152–161.
52. Cao L, Liu H, Lam DS, Yam GH, Pang CP (2010) In vitro screening for
angiostatic potential of herbal chemicals. Invest Ophthalmol Vis Sci 51: 6658–
6664.
Inhibition of RPE Cell Migration by Resveratrol
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e5681953. Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B (2009)
Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth
muscle cell migration. Am J Physiol Heart Circ Physiol 297: H874–886.
54. Kim DS, Kwon HM, Choi JS, Kang SW, Ji GE, et al. (2007) Resveratrol blunts
tumor necrosis factor-alpha-induced monocyte adhesion and transmigration.
Nutr Res Pract 1: 285–290.
55. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, Daniel WG, et al. (2011)
Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents
spontaneous endothelial cell migration through Rho kinase-dependent mecha-
nism. J Atheroscler Thromb 18: 1031–1042.
56. Tang FY, Su YC, Chen NC, Hsieh HS, Chen KS (2008) Resveratrol inhibits
migration and invasion of human breast-cancer cells. Mol Nutr Food Res 52:
683–691.
57. Lee MF, Pan MH, Chiou YS, Cheng AC, Huang H (2011) Resveratrol
modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth
factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells.
J Agric Food Chem 59: 11853–11861.
58. Ong ET, Hwang TL, Huang YL, Lin CF, Wu WB (2011) Vitisin B, a resveratrol
tetramer, inhibits migration through inhibition of PDGF signaling and
enhancement of cell adhesiveness in cultured vascular smooth muscle cells.
Toxicol Appl Pharmacol 256: 198–208.
59. Scheiffarth OF, Kampik A, Gunther H, von der Mark K (1988) Proteins of the
extracellular matrix in vitreoretinal membranes. Graefes Arch Clin Exp
Ophthalmol 226: 357–361.
60. Hinton DR, He S, Graf K, Yang D, Hsueh WA, et al. (1998) Mitogen-activated
protein kinase activation mediates PDGF-directed migration of RPE cells. Exp
Cell Res 239: 11–15.
61. Smith-Thomas L, Richardson P, Parsons MA, Rennie IG, Benson M, et al.
(1996) Additive effects of extra cellular matrix proteins and platelet derived
mitogens on human retinal pigment epithelial cell proliferation and contraction.
Curr Eye Res 15: 739–748.
62. Haugland HK, Tysnes BB, Tysnes OB (1997) Adhesion and migration of human
glioma cells are differently dependent on extracellular matrix molecules.
Anticancer Res 17: 1035–1042.
63. Wagner M, Benson MT, Rennie IG, MacNeil S (1995) Effects of pharmaco-
logical modulation of intracellular signalling systems on retinal pigment
epithelial cell attachment to extracellular matrix proteins. Curr Eye Res 14:
373–384.
64. Powell RJ, Carruth JA, Basson MD, Bloodgood R, Sumpio BE (1996) Matrix-
specific effect of endothelial control of smooth muscle cell migration. J Vasc Surg
24: 51–57.
Inhibition of RPE Cell Migration by Resveratrol
PLOS ONE | www.plosone.org 13 February 2013 | Volume 8 | Issue 2 | e56819